TY - JOUR
T1 - Platelet-Rich Fibrin–Augmented Gap-Bridging Strategy in Rabbit Anterior Cruciate Ligament Repair
AU - Weng, Pei Wei
AU - Chen, Chih Hwa
AU - Lin, Yi Cheng
AU - Chen, Kuan Hao
AU - Yeh, Yi Yen
AU - Lai, Jen Ming
AU - Chiang, Chang Jung
AU - Wong, Chin Chean
N1 - Funding Information:
One or more of the authors has declared the following potential conflict of interest or source of funding: This research was financially supported by Taipei Medical University Shuang Ho Hospital Grant (109-YSR-02). AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.
Publisher Copyright:
© 2023 The Author(s).
PY - 2023/3
Y1 - 2023/3
N2 - Background: We assessed the efficacy of a novel platelet-rich fibrin (PRF)–augmented repair strategy for promoting biological healing of an anterior cruciate ligament (ACL) midsubstance tear in a rabbit model. The biological gap-bridging effect of a PRF scaffold alone or in combination with rabbit ligamentocytes on primary ACL healing was evaluated both in vitro and in vivo. Hypothesis: A PRF matrix can be implanted as a provisional fibrin-platelet bridging scaffold at an ACL defect to facilitate functional healing. Study Design: Controlled laboratory study. Methods: The biological effects of PRF on primary rabbit ligamentocyte proliferation, tenogenic differentiation, migration, and tendon-specific matrix production were investigated for treatment of cells with PRF-conditioned medium (PRFM). Three-dimensional (3D) lyophilized PRF (LPRF)–cell composite was fabricated by culturing ligamentocytes on an LPRF patch for 14 days. Cell-scaffold interactions were investigated under a scanning electron microscope and through histological analysis. An ACL midsubstance tear model was established in 3 rabbit groups: a ruptured ACL was treated with isolated suture repair in group A, whereas the primary repair was augmented with LPRF and LPRF-cell composite to bridge the gap between ruptured ends of ligaments in groups B and C, respectively. Outcomes—gross appearance, magnetic resonance imaging, and histological analysis—were evaluated in postoperative weeks 8 and 12. Results: PRFM promoted cultured ligamentocyte proliferation, migration, and expression of tenogenic genes (type I and III collagen and tenascin). PRF was noted to upregulate cell tenogenic differentiation in terms of matrix production. In the 3D culture, viable cells formed layers at high density on the LPRF scaffold surface, with notable cell ingrowth and abundant collagenous matrix depositions. Moreover, ACL repair tissue and less articular cartilage damage were observed in knee joints in groups B and C, implying the existence of a chondroprotective phenomenon associated with PRF-augmented treatment. Conclusion: Our PRF-augmented strategy can facilitate the formation of stable repair tissue and thus provide gap-bridging in ACL repair. Clinical Relevance: From the translational viewpoint, effective primary repair of the ACL may enable considerable advancement in therapeutic strategy for ACL injuries, particularly allowing for proprioception retention and thus improved physiological joint kinematics.
AB - Background: We assessed the efficacy of a novel platelet-rich fibrin (PRF)–augmented repair strategy for promoting biological healing of an anterior cruciate ligament (ACL) midsubstance tear in a rabbit model. The biological gap-bridging effect of a PRF scaffold alone or in combination with rabbit ligamentocytes on primary ACL healing was evaluated both in vitro and in vivo. Hypothesis: A PRF matrix can be implanted as a provisional fibrin-platelet bridging scaffold at an ACL defect to facilitate functional healing. Study Design: Controlled laboratory study. Methods: The biological effects of PRF on primary rabbit ligamentocyte proliferation, tenogenic differentiation, migration, and tendon-specific matrix production were investigated for treatment of cells with PRF-conditioned medium (PRFM). Three-dimensional (3D) lyophilized PRF (LPRF)–cell composite was fabricated by culturing ligamentocytes on an LPRF patch for 14 days. Cell-scaffold interactions were investigated under a scanning electron microscope and through histological analysis. An ACL midsubstance tear model was established in 3 rabbit groups: a ruptured ACL was treated with isolated suture repair in group A, whereas the primary repair was augmented with LPRF and LPRF-cell composite to bridge the gap between ruptured ends of ligaments in groups B and C, respectively. Outcomes—gross appearance, magnetic resonance imaging, and histological analysis—were evaluated in postoperative weeks 8 and 12. Results: PRFM promoted cultured ligamentocyte proliferation, migration, and expression of tenogenic genes (type I and III collagen and tenascin). PRF was noted to upregulate cell tenogenic differentiation in terms of matrix production. In the 3D culture, viable cells formed layers at high density on the LPRF scaffold surface, with notable cell ingrowth and abundant collagenous matrix depositions. Moreover, ACL repair tissue and less articular cartilage damage were observed in knee joints in groups B and C, implying the existence of a chondroprotective phenomenon associated with PRF-augmented treatment. Conclusion: Our PRF-augmented strategy can facilitate the formation of stable repair tissue and thus provide gap-bridging in ACL repair. Clinical Relevance: From the translational viewpoint, effective primary repair of the ACL may enable considerable advancement in therapeutic strategy for ACL injuries, particularly allowing for proprioception retention and thus improved physiological joint kinematics.
KW - anterior cruciate ligament
KW - augmentation
KW - platelet-rich fibrin
KW - primary repair
UR - http://www.scopus.com/inward/record.url?scp=85147772092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147772092&partnerID=8YFLogxK
U2 - 10.1177/03635465221149993
DO - 10.1177/03635465221149993
M3 - Article
AN - SCOPUS:85147772092
SN - 0363-5465
VL - 51
SP - 642
EP - 655
JO - American Journal of Sports Medicine
JF - American Journal of Sports Medicine
IS - 3
ER -